Haisco News & Analysis

Sentivera Founded with $76M Immunology Asset from Haisco

Population Health Partners and ARCH Venture Partners have established Sentivera, a US biotech, following a $76 million upfront payment to Haisco Pharmaceutical for an immunology asset. The total deal could exceed $1.5 billion with additional milestone payments. Haisco’s asset is aimed at treating type 2 inflammatory diseases and has recently received authorization to enter clinical trials in China. This investment reflects an increasing trend of collaboration between Chinese drug developers and US pharmaceutical companies, which could impact future market dynamics for biotech investments.